上海皓元医药股份有限公司股东冻结股份被动减持计划公告
公告核心内容
- 公司股东新余诚众棠投资管理中心（有限合伙）持有公司4,065,208股股份，占公司总股本的1.92%。该部分股份为首次公开发行前及上市后权益分派资本公积转增股本取得，已上市流通，目前处于冻结状态。
- 由于司法强制执行，证券公司将协助处置新余诚众棠持有的股份，计划在2026年5月29日至2026年8月28日三个月内通过集中竞价交易方式减持不超过2,121,039股，占公司总股本的比例不超过1%。
详细解读
1. 股东减持背景：
新余诚众棠投资管理中心（有限合伙）并非控股股东、实际控制人或一致行动人，也不是公司董事、监事或高级管理人员。其持股来源为IPO前及上市后资本公积转增股本，曾做出锁定期及减持意向承诺。此次减持属于司法强制执行，由证券公司根据浙江省杭州市拱墅区人民法院的《协助执行通知书》依法协助处置该部分股份。
2. 减持计划细节：
- 计划减持数量：不超过2,121,039股，占公司总股本的1%。
- 减持方式：集中竞价交易。
- 减持期间：2026年5月29日～2026年8月28日。
- 减持股份来源：IPO前及上市后权益分派资本公积转增股本取得的股份。
- 减持原因：司法强制执行。
- 若公司股票停牌，减持时间将顺延。
3. 股东承诺与合规情况：
新余诚众棠曾承诺上市后12个月内不转让或委托管理发行前股份，承诺严格遵守减持相关法律法规，并将在实施减持前提前公告。如违反承诺，需纠正并承担法律责任，并将收益全部上缴公司。此次减持与已披露承诺一致。
4. 风险提示及对投资者的重要影响：
- 本次减持属于被动司法处置，股份变动时间及价格存在不确定性，实际执行情况以最终结果为准。
- 此次减持不会引发公司控制权变更。
- 新余诚众棠将严格遵守《证券法》及相关减持规定，及时履行信息披露义务。
- 减持规模占总股本的1%，属于中等规模，若集中减持可能对公司股价形成短期压力，投资者需关注减持进展及市场反应。
投资者需关注的重要事项
- 减持行为为司法强制执行，非股东主动减持，但短期内可能对公司股价有影响。
- 涉及股份占比虽不大，但集中竞价减持或引发市场波动。
- 公司控制权不受影响，但投资者需关注减持进度及相关公告。
- 若有停牌情况，减持时间将顺延，投资者需留意公告更新。
结论
本公告披露了皓元医药重要股东因司法强制执行被动减持股份的计划，对公司股价有潜在影响，投资者需密切关注减持进展及市场反应，做好风险防范。
免责声明：本文仅为信息披露与投资参考，不构成任何投资建议。投资者需结合自身情况理性判断，注意市场风险。
Shanghai Haoyuan Pharmaceutical Co., Ltd. Shareholder Forced Share Reduction Plan Announcement – In-depth Analysis
Key Points of the Announcement
- Shareholder Xinyu Chengzhong Tang Investment Management Center (Limited Partnership) holds 4,065,208 shares of the company, accounting for 1.92% of total share capital. These shares were obtained before IPO and through conversion of capital reserves after listing, have been listed, and are now frozen.
- Due to judicial enforcement, the securities company will assist in disposing these shares. The plan is to reduce no more than 2,121,039 shares (not more than 1% of total share capital) via block trading from May 29, 2026, to August 28, 2026.
Detailed Analysis
1. Background of Share Reduction:
Xinyu Chengzhong Tang Investment Management Center is not a controlling shareholder, actual controller, or acting in concert, nor a director, supervisor, or senior manager. The shares were obtained pre-IPO or through post-listing capital reserve conversion. Previous lock-up and reduction intent commitments were made. This reduction is a forced judicial execution, with the securities company assisting under a Zhejiang court enforcement notice.
2. Reduction Plan Details:
- Reduction amount: No more than 2,121,039 shares (1% of total share capital).
- Method: Block trading.
- Period: May 29, 2026, to August 28, 2026.
- Source: Pre-IPO and post-listing capital reserve conversion shares.
- Reason: Judicial enforcement.
- If shares are suspended, reduction timing will be postponed accordingly.
3. Shareholder Commitment & Compliance:
Xinyu Chengzhong Tang had committed not to transfer or entrust pre-IPO shares within 12 months post-listing, to strictly comply with regulations when reducing holdings, and to announce reductions in advance. If violated, they must correct and bear legal responsibility, with all proceeds handed over to the company. This reduction is consistent with previous commitments.
4. Risk Alerts & Key Points for Investors:
- This reduction is a forced judicial disposal, with timing and price uncertainties. Final execution prevails.
- Will not cause a change in company control.
- Xinyu Chengzhong Tang will strictly follow securities laws and reduction regulations, with timely disclosures.
- The reduction size is moderate (1% of total shares); block trading may exert short-term pressure on share price, so investors should monitor progress and market response.
Important Matters for Investors
- The reduction is court-enforced, not voluntary, but may impact share price in the short term.
- The reduction proportion is not large, but block trading could trigger market volatility.
- Company control is unaffected, but investors should monitor reduction progress and related announcements.
- If there is a suspension, reduction period will be postponed; follow up for updates.
Conclusion
This announcement reveals that a key shareholder will have shares reduced by judicial enforcement, potentially impacting Haoyuan Pharmaceutical’s share price. Investors should closely follow reduction progress and market reactions, and manage risks accordingly.
Disclaimer: This article is for information disclosure and investment reference only and does not constitute investment advice. Investors should make rational judgments based on their own circumstances and pay attention to market risks.
